

AGM 2024

Magnus Groth
President and CEO



A large, diverse group of people of various ages, ethnicities, and abilities are posed together against a solid pink background. The group includes an elderly man, a woman in a wheelchair, a young child, a pregnant woman, a woman with a cast on her leg, and many others. The text "For everybody and every body" is overlaid in white across the center of the group.

For everybody and every body

Every day our brands care for the hygiene and health of a billion people across 150 countries

Essity – A Leading Hygiene and Health Company

147 Net sales 2023
SEKbn

150 Sales in
countries

36,000 employees


72 Production
facilities

A Decade of Continuous Change




A Decade of Strong Financial Development

Sales



Result¹⁾



¹⁾EBITA excluding items affecting comparability
2014-2020 Excluding Vinda's published figures; 2021-2023 Vinda classified as discontinued operations.

Result 2023

High Sales
Growth

+6.7%

Organic and
Acquisitions

Record High
Profit

EBITA¹⁾

18.9

SEKbn

Improved
Return

ROCE¹⁾

16.4%

¹⁾ Excluding items affecting comparability

Proposed Increased Dividend

Proposed Dividend¹⁾

SEK 7.75
per share
+7%



¹⁾ Proposed by the Board of Directors

Divestment Vinda

Sales Proceeds

SEK ~19bn

Annual Return

~14%

on Investment



Press release

Stockholm, March 21, 2024

Essity completes divestment of its shares in Vinda

The hygiene and health company Essity has today completed the divestment of its entire holding of 51.59% of shares in the Asian hygiene company Vinda International Holdings Limited (Vinda) for HKD 23.50 per share. The sales proceeds amounted to HKD 14.6bn (approximately SEK 19bn). Essity will retain a presence in Asia and in Vinda through continued licensing of Essity's brands.

On December 15, 2023, Essity communicated that Isola Castle Ltd, a company indirectly wholly owned by Asia Pacific Resources International Limited (APRIL), had announced that it intended to make a pre-conditional public offer to the shareholders of Vinda to acquire 100% of the company's issued shares for HKD 23.50 per share. Essity signed an irrevocable undertaking to accept the offer in respect of all of its 51.59% shareholding. The offer was announced on March 8, 2024, and Essity has accepted it in line with its undertaking. The price in the public offer will correspond to an equity value for all shares of approximately HKD 28.3bn (SEK 37bn).

"Essity is now in better shape than ever. Following the divestment of Vinda, the categories with the highest margins and lowest capital intensity account for a larger part of the company. The company's pulp consumption has halved, and we have a more attractive portfolio with higher profitability and lower volatility. The transaction reduced Consumer Tissue's share of net sales in 2023 from 41% to 33%. We look forward to continuing to grow a portfolio of more value-generating categories," says Magnus Groth, President and CEO for Essity.

2024 – Essity in Better Shape than Ever

More efficient production

Lower volatility

Pricing power

More profitable and attractive portfolio

Strong financial position

2024 – Continued Favorable Market Trends

**Aging and
Growing Population**

**Awareness about
Hygiene and Health**

**Prevalence of
Chronic Conditions**



2024 – Focus on Profitable Volume Growth

Health & Medical



Accelerate growth for increased economies of scale

Consumer Goods



Grow high-margin segments

Professional Hygiene



Exceed market growth from leading position

Invest in Essity

Well positioned for profitable growth



Attractive and growing markets



Leading brands and innovations



Sustainability in focus



Strong financial position



For everybody
and every body

This presentation may contain forward-looking statements. Such statements are based on our current expectations and are subject to certain risks and uncertainties that could negatively affect our business. Please read our most recent annual report for a better understanding of these risks and uncertainties.



